iRhythm Technologies Announces Director Change and Executive Compensation
Ticker: IRTC · Form: 8-K · Filed: Jan 27, 2025 · CIK: 1388658
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
Related Tickers: IRTC
TL;DR
Board shuffle and exec comp details out of iRhythm. #governance
AI Summary
On January 23, 2025, iRhythm Technologies, Inc. announced the departure of director Dr. Michael J. McDevitt and the appointment of Dr. Jennifer L. Collins as a new Class III director. The company also disclosed compensatory arrangements for its named executive officers, including base salary, potential cash bonuses, and equity awards.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance matters and executive compensation, with no immediate financial distress or significant operational changes indicated.
Key Players & Entities
- iRhythm Technologies, Inc. (company) — Registrant
- Dr. Michael J. McDevitt (person) — Departing Director
- Dr. Jennifer L. Collins (person) — Appointed Director
FAQ
Who is Dr. Jennifer L. Collins and what is her background?
The filing does not provide specific details about Dr. Jennifer L. Collins' background or qualifications beyond her appointment as a Class III director.
What are the specific compensatory arrangements for the named executive officers?
The filing mentions base salary, potential cash bonuses, and equity awards for named executive officers but does not detail the specific amounts or terms within this document.
When was Dr. Michael J. McDevitt's departure effective?
The filing indicates the date of the earliest event reported is January 23, 2025, suggesting this is the effective date of Dr. McDevitt's departure.
What is the term of Dr. Jennifer L. Collins' directorship?
Dr. Jennifer L. Collins has been appointed as a Class III director, but the specific term length is not detailed in this filing.
Are there any other changes to the board of directors or executive officers mentioned?
This filing specifically reports the departure of Dr. Michael J. McDevitt and the appointment of Dr. Jennifer L. Collins, along with compensatory arrangements for certain officers.
Filing Stats: 474 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2025-01-27 16:48:50
Key Financial Figures
- $0.001 — ich registered Common Stock, Par Value $0.001 Per Share IRTC The NASDAQ Global Select
Filing Documents
- irtc-20250123.htm (8-K) — 21KB
- 0001388658-25-000005.txt ( ) — 145KB
- irtc-20250123.xsd (EX-101.SCH) — 2KB
- irtc-20250123_lab.xml (EX-101.LAB) — 22KB
- irtc-20250123_pre.xml (EX-101.PRE) — 13KB
- irtc-20250123_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IRHYTHM TECHNOLOGIES, INC. Date: January 27, 2025 By: /s/ Daniel Wilson Daniel Wilson Chief Financial Officer